FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079596300> ?p ?o ?g. }

• W2079596300 endingPage "1829" @default.
• W2079596300 startingPage "1825" @default.
• W2079596300 abstract "Purpose Endovascular management of limb-threatening ischemia often requires treatment of tibial occlusive disease. This study was preformed to examine the patency of drug-eluting tibial stents. Materials and Methods The medical records of all patients undergoing drug-eluting tibial stent placement for limb-threatening ischemia from June 2004 to June 2008 were retrospectively reviewed. Postprocedural antiplatelet therapy included clopidogrel and aspirin. Patients were followed with serial arterial duplex ultrasonography and had selective subsequent angiographic evaluation based on noninvasive findings. Primary patency of the target lesion, limb salvage, and survival rates were reported. Results A total of 240 patients underwent 283 tibial angioplasty procedures to treat limb-threatening ischemia during the 4-year period. Fifty-two patients (22%) had a suboptimal balloon result and were treated with a drug-eluting tibial stent. Balloon-expandable paclitaxel-eluting stents were used in all patients (1.2 stents per patient; range, 1–3; median diameter, 2.75 mm; range, 2.5–3.5 mm; median length, 24 mm; range, 20–32 mm). Forty-eight of those 52 patients (92%) had simultaneous endovascular treatment of proximal lesions. Mean follow-up was 14.3 months (range, 1–48 months). Target lesion patency of the drug-eluting tibial stent was 73% at 24 months (SE < 10%). Limb salvage rate in patients treated with drug-eluting tibial stents was 86% at 26 months (SE < 10%), and the survival rate was 65% at 24 months (SE < 10%). Conclusions Drug-eluting tibial stents are a viable option for the endovascular management of limb-threatening ischemia and have acceptable patency rates. The majority of patients require multilevel endovascular treatment, and close surveillance is required for limb salvage. Endovascular management of limb-threatening ischemia often requires treatment of tibial occlusive disease. This study was preformed to examine the patency of drug-eluting tibial stents. The medical records of all patients undergoing drug-eluting tibial stent placement for limb-threatening ischemia from June 2004 to June 2008 were retrospectively reviewed. Postprocedural antiplatelet therapy included clopidogrel and aspirin. Patients were followed with serial arterial duplex ultrasonography and had selective subsequent angiographic evaluation based on noninvasive findings. Primary patency of the target lesion, limb salvage, and survival rates were reported. A total of 240 patients underwent 283 tibial angioplasty procedures to treat limb-threatening ischemia during the 4-year period. Fifty-two patients (22%) had a suboptimal balloon result and were treated with a drug-eluting tibial stent. Balloon-expandable paclitaxel-eluting stents were used in all patients (1.2 stents per patient; range, 1–3; median diameter, 2.75 mm; range, 2.5–3.5 mm; median length, 24 mm; range, 20–32 mm). Forty-eight of those 52 patients (92%) had simultaneous endovascular treatment of proximal lesions. Mean follow-up was 14.3 months (range, 1–48 months). Target lesion patency of the drug-eluting tibial stent was 73% at 24 months (SE < 10%). Limb salvage rate in patients treated with drug-eluting tibial stents was 86% at 26 months (SE < 10%), and the survival rate was 65% at 24 months (SE < 10%). Drug-eluting tibial stents are a viable option for the endovascular management of limb-threatening ischemia and have acceptable patency rates. The majority of patients require multilevel endovascular treatment, and close surveillance is required for limb salvage." @default.
• W2079596300 created "2016-06-24" @default.
• W2079596300 creator A5009841726 @default.
• W2079596300 creator A5012377209 @default.
• W2079596300 creator A5019203738 @default.
• W2079596300 creator A5023908373 @default.
• W2079596300 creator A5073092071 @default.
• W2079596300 creator A5081510643 @default.
• W2079596300 date "2010-12-01" @default.
• W2079596300 modified "2023-09-25" @default.
• W2079596300 title "Drug-eluting Tibial Stents: Objective Patency Determination" @default.
• W2079596300 cites W1971601137 @default.
• W2079596300 cites W2001434548 @default.
• W2079596300 cites W2032371957 @default.
• W2079596300 cites W2034024074 @default.
• W2079596300 cites W2035229961 @default.
• W2079596300 cites W2043517681 @default.
• W2079596300 cites W2053492914 @default.
• W2079596300 cites W2068502485 @default.
• W2079596300 cites W2075517826 @default.
• W2079596300 cites W2090246923 @default.
• W2079596300 cites W2104337019 @default.
• W2079596300 cites W2116362164 @default.
• W2079596300 cites W2132880199 @default.
• W2079596300 cites W2161806128 @default.
• W2079596300 cites W2165192500 @default.
• W2079596300 cites W4248693543 @default.
• W2079596300 cites W4256736650 @default.
• W2079596300 doi "https://doi.org/10.1016/j.jvir.2010.09.011" @default.
• W2079596300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20961774" @default.
• W2079596300 hasPublicationYear "2010" @default.
• W2079596300 type Work @default.
• W2079596300 sameAs 2079596300 @default.
• W2079596300 citedByCount "11" @default.
• W2079596300 countsByYear W20795963002012 @default.
• W2079596300 countsByYear W20795963002013 @default.
• W2079596300 countsByYear W20795963002014 @default.
• W2079596300 countsByYear W20795963002016 @default.
• W2079596300 countsByYear W20795963002019 @default.
• W2079596300 countsByYear W20795963002020 @default.
• W2079596300 countsByYear W20795963002021 @default.
• W2079596300 crossrefType "journal-article" @default.
• W2079596300 hasAuthorship W2079596300A5009841726 @default.
• W2079596300 hasAuthorship W2079596300A5012377209 @default.
• W2079596300 hasAuthorship W2079596300A5019203738 @default.
• W2079596300 hasAuthorship W2079596300A5023908373 @default.
• W2079596300 hasAuthorship W2079596300A5073092071 @default.
• W2079596300 hasAuthorship W2079596300A5081510643 @default.
• W2079596300 hasConcept C126322002 @default.
• W2079596300 hasConcept C126838900 @default.
• W2079596300 hasConcept C139059822 @default.
• W2079596300 hasConcept C141071460 @default.
• W2079596300 hasConcept C2777466421 @default.
• W2079596300 hasConcept C2777628954 @default.
• W2079596300 hasConcept C2777849778 @default.
• W2079596300 hasConcept C2778583881 @default.
• W2079596300 hasConcept C2780326628 @default.
• W2079596300 hasConcept C2780400711 @default.
• W2079596300 hasConcept C2781099653 @default.
• W2079596300 hasConcept C2781156865 @default.
• W2079596300 hasConcept C2781464078 @default.
• W2079596300 hasConcept C3018348675 @default.
• W2079596300 hasConcept C500558357 @default.
• W2079596300 hasConcept C71924100 @default.
• W2079596300 hasConceptScore W2079596300C126322002 @default.
• W2079596300 hasConceptScore W2079596300C126838900 @default.
• W2079596300 hasConceptScore W2079596300C139059822 @default.
• W2079596300 hasConceptScore W2079596300C141071460 @default.
• W2079596300 hasConceptScore W2079596300C2777466421 @default.
• W2079596300 hasConceptScore W2079596300C2777628954 @default.
• W2079596300 hasConceptScore W2079596300C2777849778 @default.
• W2079596300 hasConceptScore W2079596300C2778583881 @default.
• W2079596300 hasConceptScore W2079596300C2780326628 @default.
• W2079596300 hasConceptScore W2079596300C2780400711 @default.
• W2079596300 hasConceptScore W2079596300C2781099653 @default.
• W2079596300 hasConceptScore W2079596300C2781156865 @default.
• W2079596300 hasConceptScore W2079596300C2781464078 @default.
• W2079596300 hasConceptScore W2079596300C3018348675 @default.
• W2079596300 hasConceptScore W2079596300C500558357 @default.
• W2079596300 hasConceptScore W2079596300C71924100 @default.
• W2079596300 hasIssue "12" @default.
• W2079596300 hasLocation W20795963001 @default.
• W2079596300 hasLocation W20795963002 @default.
• W2079596300 hasOpenAccess W2079596300 @default.
• W2079596300 hasPrimaryLocation W20795963001 @default.
• W2079596300 hasRelatedWork W1966352072 @default.
• W2079596300 hasRelatedWork W2032486274 @default.
• W2079596300 hasRelatedWork W2101733418 @default.
• W2079596300 hasRelatedWork W2165115918 @default.
• W2079596300 hasRelatedWork W231173872 @default.
• W2079596300 hasRelatedWork W2418883363 @default.
• W2079596300 hasRelatedWork W2466626607 @default.
• W2079596300 hasRelatedWork W2911984489 @default.
• W2079596300 hasRelatedWork W2918922141 @default.
• W2079596300 hasRelatedWork W3036102439 @default.
• W2079596300 hasVolume "21" @default.
• W2079596300 isParatext "false" @default.
• W2079596300 isRetracted "false" @default.

• next